株式会社Liquid Mine
Tokyo, JP · 1 known investors
Liquid Mine develops MyRD®, a liquid biopsy-based genomic testing system that creates personalized diagnostic tests for leukemia and other cancers by analyzing individual patient genetic mutations. The company aims to advance precision medicine in oncology by making genomic testing more accessible, particularly in Japan, through collaboration with Tokyo University's Institute of Medical Science.
Investors · 1
Frequently asked questions
- What does 株式会社Liquid Mine do?
- Liquid Mine develops MyRD®, a liquid biopsy-based genomic testing system that creates personalized diagnostic tests for leukemia and other cancers by analyzing individual patient genetic mutations. The company aims to advance precision medicine in oncology by making genomic testing more accessible, particularly in Japan, through collaboration with Tokyo University's Institute of Medical Science.
- Who are 株式会社Liquid Mine's investors?
- 株式会社Liquid Mine's investors include aSTART.
- Where is 株式会社Liquid Mine headquartered?
- 株式会社Liquid Mine is headquartered in Tokyo, JP.